» Articles » PMID: 17950840

Prosthetic Heart Valves: Catering for the Few

Overview
Journal Biomaterials
Date 2007 Oct 24
PMID 17950840
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Prosthetic heart valves epitomize both the triumphant advance of cardiac surgery in its early days and its stagnation into a retrospective, exclusive first world discipline of late. Fifty-two years after the first diseased heart valve was replaced in a patient, prostheses largely represent the concepts of the 1960s with many of their design-inherent complications. While the sophisticated medical systems of the developed world may be able to cope with sub-optimal replacements, these valves are poorly suited to the developing world (where the overwhelming majority of potential valve recipients reside), due to differences in age profiles and socio-economic circumstances. Therefore, it is the latter group which suffered most from the sluggish pace of developments. While it previously took less than 7 years for mechanical heart valves to develop from the first commercially available ball-in-cage valve to the tilting pyrolytic-carbon disc valve, and another 10 years to arrive at the all-carbon bi-leaflet design, only small incremental improvements have been achieved since 1977. Similarly, bioprosthetic valves saw their last major break-through development in the late 1960s when formalin fixation was replaced by glutaraldehyde cross linking. Since then, poorly understood so-called 'anti-calcification' treatments were added and the homograft concept rediscovered under the catch-phrase 'stentless'. Still, tissue valves continue to degenerate fast in younger patients, making them unsuitable for developing countries. Yet, catheter-delivered prostheses almost exclusively use bioprosthetic tissue, thereby reducing one of the most promising developments for patients of the developing world into a fringe product for the few first world recipients. With tissue-engineered valves aiming at the narrow niche of congenital malformations and synthetic flexible leaflet valves being in their fifth decade of low-key development, heart valve prostheses seem to be destined to remain an unsatisfying and exclusive first world solution for a long time to come.

Citing Articles

Rethinking mechanical heart valves in the aortic position: new paradigms in design and testing.

Chakraborty S, Simon M, Bellofiore A Front Cardiovasc Med. 2025; 11:1458809.

PMID: 39949724 PMC: 11822478. DOI: 10.3389/fcvm.2024.1458809.


Calcific aortic stenosis: omics-based target discovery and therapy development.

Blaser M, Back M, Luscher T, Aikawa E Eur Heart J. 2024; 46(7):620-634.

PMID: 39656785 PMC: 11825147. DOI: 10.1093/eurheartj/ehae829.


A value hierarchy for inclusive design of heart valve implants in regenerative medicine.

De Kanter A, van Daal M, Gunn C, Bredenoord A, de Graeff N, Jongsma K Regen Med. 2024; 19(6):289-301.

PMID: 39177570 PMC: 11346526. DOI: 10.1080/17460751.2024.2357500.


Mechanical valve replacement for patients with rheumatic heart disease: the reality of INR control in Africa and beyond.

Zilla P, Human P, Pennel T Front Cardiovasc Med. 2024; 11:1347838.

PMID: 38404722 PMC: 10884232. DOI: 10.3389/fcvm.2024.1347838.


Development and testing of a transcatheter heart valve with reduced calcification potential.

Weich H, Botes L, Doubell A, Jordaan J, Lewies A, Marimuthu P Front Cardiovasc Med. 2023; 10:1270496.

PMID: 38124891 PMC: 10731034. DOI: 10.3389/fcvm.2023.1270496.